Results 101 to 110 of about 2,667 (188)
Translating biomarker insights into practice: a path forward in TA-TMA management
Recent advances in the management of transplant-associated thrombotic microangiopathy (TA-TMA) include the harmonization of diagnostic criteria and the identification of high-risk disease features.
Sonata Jodele, Eleni Gavriilaki
doaj +1 more source
Ravulizumab and Efgartigimod in Myasthenia Gravis
Finanziert durch den Open-Access-Publikationsfonds der Universität Münster.
Frauke Stascheit +16 more
openaire +4 more sources
Refocusing generalized myasthenia gravis : Patient burden, disease profiles, and the role of evolving therapy [PDF]
Generalized myasthenia gravis (gMG) continues to present significant challenges for clinical management due to an unpredictable disease course, frequent disease fluctuations, and varying response to therapy.
Cortés-Vicente, Elena +5 more
core +1 more source
Key Clinical Message Haploidentical hematopoietic stem cell transplantation (HSCT) with posttransplant cyclophosphamide is an alternative treatment for aplastic anemia–paroxysmal nocturnal hemoglobinuria (PNH) syndrome with poor prognostic factors ...
Kazuki Sakurai +6 more
doaj +1 more source
New drugs for acute kidney injury. [PDF]
Acute kidney injury (AKI) presents a significant challenge in the management of critically ill patients, as it is associated with increased mortality, prolonged hospital stays, and increased healthcare costs.
Hariri, Geoffroy, Legrand, Matthieu
core +1 more source
Background Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, chronic blood disorder. Symptoms such as fatigue can have a substantial impact on patients’ physical activity levels, sleep, quality of life, and work productivity. Ravulizumab treatment can
Elizabeth A. Griffiths +6 more
doaj +1 more source
Treating myasthenia gravis beyond the eye clinic [PDF]
Myasthenia gravis (MG) is one of the most well characterised autoimmune disorders affecting the neuromuscular junction with autoantibodies targeting the acetylcholine receptor (AChR) complex.
Jacob, Saiju
core +1 more source
Key Clinical Message This unique case of generalized myasthenia gravis shows sustained stability of a patient's condition for 3 years with eculizumab/ravulizumab treatment following 16 years of refractory disease.
Stefan Quasthoff
doaj +1 more source
Background Cardiac procedures, particularly those requiring cardiopulmonary bypass (CPB), are associated with the development of cardiac surgery-associated acute kidney injury (CSA-AKI).
Marlies Ostermann +13 more
doaj +1 more source

